SUP-T1 Cells
USD$430.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | SUP-T1 is a human T-cell lymphoblastic lymphoma (T-LBL) cell line derived from the pleural effusion of a child diagnosed with T-cell non-Hodgkin lymphoma. It carries the characteristic t(8;14)(q24;q11) chromosomal translocation, which juxtaposes the MYC oncogene to the T-cell receptor alpha/delta (TCRα/δ) locus. This translocation leads to MYC overexpression, promoting cellular proliferation and inhibiting apoptosis, which are key drivers of lymphomagenesis. Due to this genetic hallmark, SUP-T1 serves as an important model for studying the molecular mechanisms underlying aggressive T-cell malignancies and testing targeted therapies. Genomic analyses of SUP-T1 have identified additional oncogenic alterations, including deletions and rearrangements affecting the CDKN2A gene, a critical tumor suppressor involved in cell cycle regulation. Loss of CDKN2A leads to dysregulated cell cycle progression, further contributing to the aggressive phenotype of this lymphoma. These findings make SUP-T1 a valuable model for investigating both MYC-driven oncogenesis and the role of tumor suppressor loss in T-cell malignancies. Recent studies utilizing next-generation sequencing (NGS) and transcriptomic profiling have provided deeper insights into the viral status and mutational landscape of SUP-T1. Screening for viral sequences using RNA-Seq data has confirmed that SUP-T1 is free of Epstein-Barr virus (EBV) and other common viral contaminants, ensuring its reliability for controlled in vitro experiments. Additionally, its genetic profile has been incorporated into large-scale pharmacogenomic datasets, which facilitate the identification of targeted therapeutic strategies for T-cell lymphomas. SUP-T1 continues to be a crucial tool in preclinical research, particularly in the development of novel treatments for aggressive T-cell malignancies. |
|---|---|
| Organism | Human |
| Tissue | Pleural effusion |
| Disease | Lymphoblastic Lymphoma; T-cell |
| Synonyms | Sup-T1, SUPT-1, SupT-1, Sup T-1, SUP T-1, SUP T1, Sup T1, SupT1, SUPT1, Tsup-1, VB, Stanford University Pediatric T-cell line 1 |
Characteristics
| Age | 8 years |
|---|---|
| Gender | Male |
| Ethnicity | Caucasian |
| Morphology | Lymphoblast |
| Cell type | T lymphoblast |
| Growth properties | Suspension |
Regulatory Data
| Citation | SUP-T1 (Cytion catalog number 305642) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_1714 |
Biomolecular Data
| Protein expression | Immunoglobulin (cytoplasmic) |
|---|---|
| Antigen expression | Leu-6 (CD1a) +; Leu-4 (CD3) +; Leu-3 (CD4) +; Leu-1 (CD5) +; Leu-9 (CD7) +; Leu-2a (CD8) +; OKT-10 (CD38) + |
| Mutational profile | Mutation: EGFR, Simple, p.Cys251Tyr (c.752G>A), Heterozygous; Mutation: KIT, Simple, p.Arg177His (c.530G>A), Heterozygous; Mutation: MET, Simple, p.Arg191Trp (c.571C>T), Heterozygous; Mutation: PIK3CA, Simple, p.Glu545Asp (c.1635G>T), Heterozygous; Mutation: PIK3CA, Simple, p.Glu970Lys (c.2908G>A), Heterozygous; Mutation: PTCH1, Simple, p.Arg682Cys (c.2044C>T), Heterozygous; Mutation: SPRY4, Simple, p.Arg25Trp (c.73C>T), Heterozygous; Mutation: TP53, Simple, p.Arg267Leu (c.800G>T), Heterozygous |
| Karyotype | 92, XXYY, -2, -2, -9, -9, the following markers are present: 2inv(2*) (p21q11), +2inv(2*), del(2*)(Q21), 2del(4)(q31q35), 2del(5)(p13p14), 2del(6)(q23q27), 2inv(14)(q11q32), t(7;9)(q34;q34), der(9)t(7;9) |
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Doubling time | 28 hours |
| Seeding density | 2-5 x105 cells/mL |
| Fluid renewal | 2 to 3 times per week |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|